Hydroxamic Acid Or Salt Thereof Patents (Class 514/575)
-
Publication number: 20030073689Abstract: A composition in the form of an ultrafine oil-in-water emulsion in which the mean size of the oil globules ranges from 50 nm to 1000 nm containing a haloalkynyl derivative, preferably 3-iodo-2-propynyl butylcarbamate.Type: ApplicationFiled: September 26, 2002Publication date: April 17, 2003Applicant: L'OREALInventor: Jerome Senee
-
Publication number: 20030073722Abstract: This invention is in the field of antiinflammatory pharmaceutical agents and specifically relates to compounds, compositions and methods for treating disorders mediated by cyclooxygenase-2 or 5-lipoxygenase, such as inflammation.Type: ApplicationFiled: July 8, 2002Publication date: April 17, 2003Applicant: Pharmacia CorporationInventors: John J. Talley, James A. Sikorski, Matthew J. Graneto, Bryan H. Norman, Balekudru Devadas, Hwang-Fun Lu
-
Publication number: 20030073660Abstract: The invention refers to a synthetic double-stranded oligonucleotide having a length comprised between 10 and 50 bases and a nucleic acid sequence selected from the group consisting of: (a) sequences corresponding to a selected portion of the promoter of human &ggr;-globin gene; and (b) sequences corresponding to a selected portion of the human genomic region comprised between the &ggr;-globin gene and the &dgr;&bgr;-cluster, for use as an inducer of erythroid differentiation.Type: ApplicationFiled: September 13, 2002Publication date: April 17, 2003Inventors: Nicoletta Bianchi, Giordana Feriotto, Roberto Gambari, Carlo Mischiati
-
Publication number: 20030068386Abstract: This invention discloses a method of treating a patient having a cancerous disease comprising administering to the patient an effective amount of a composition capable of generating a hydroxyl radical, wherein the extracellular pH of the cancer cells is less than 7.0. Preferably, the method includes employing N-substituted hydroxyl amines as the composition capable of generating the hydroxyl radical.Type: ApplicationFiled: September 5, 2001Publication date: April 10, 2003Inventor: Detcho A. Stoyanovsky
-
Patent number: 6545051Abstract: A method for the treatment of bacterial infections in humans and non-human mammals, which comprises administering to a subject suffering such infection an antibacterial effective dose of a compound of formula (I): wherein R1 represents hydrogen, hydroxy, amino, methyl, or trifluoromethyl; R2 represents a group R10—(X)n—(ALK)— wherein R10 represents hydrogen, a C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, aryl, or heterocyclyl group, ALK represents a straight or branched divalent C1-C6 alkylene, C2-C6 alkenylene, C2-C6 alkynylene radical, and may be interrupted by one or more non-adjacent —NH—, —O— or —S— linkages; X represents —NH—, —O— or —S—, and n is 0 or 1; R represents hydrogen or C1-C6 alkyl; R3 represents the characterising group of a natural or non-natural &agr; amino acid in which any functional groups may be protected; and R4 represents an ester or thioester group.Type: GrantFiled: July 20, 2001Date of Patent: April 8, 2003Assignee: British Biotech Pharmaceuticals, Ltd.Inventors: Michael George Hunter, Raymond Paul Beckett, John Martin Clements, Mark Whittaker
-
Patent number: 6534501Abstract: Chemical structures have been identified which allosterically modify pyrvate kinase and inhibit enzymatic activity. These compounds can be used as pharmaceuticals in the treatment of a wide variety of diseases and disorders where influencing metabolic processes is beneficial, such as the glycolytic pathway, all pathways which use ATP as an energy source, and all pathways which involve 2,3-diphosphoglycerate related to the delivery of oxygen by modifying hemoglobin's oxygen affinity, treatments of tumor and cancer and Alzheimer's disease (AD).Type: GrantFiled: March 7, 2001Date of Patent: March 18, 2003Assignees: Allos Therapeutics, Inc., Virginia Commonwealth UniversityInventors: Donald J. Abraham, Changging Wang, Richmond Danso-Danquah, James C. Burnett, Gajanan S. Joshi, Stephen J. Hoffman
-
Publication number: 20030049272Abstract: A pharmaceutical composition which reduces or eliminates the drug abuse potential of central nervous system stimulant comprising: (a) a central nervous system stimulant selected from the group consisting of methylphenidate, amphetamine, methamphetamine, and combinations thereof; and (b) a mucous membrane irritant selected from the group consisting of organic and inorganic acid, salt, ketone, nitrite, sulfide, bisulfate, persulfate, glycerophosphate, hypophosphate, borate, titanate, amino acid, peptide, and combinations thereof, wherein the mucous membrane irritant produces irritation when contacted with the skin or mucous membrane.Type: ApplicationFiled: August 30, 2001Publication date: March 13, 2003Inventors: Yatindra Joshi, Russell Somma
-
Publication number: 20030049255Abstract: The invention pertains to methods for treating medical disorders characterized by elevated levels or abnormal expression of IL-1 by administering an IL-1 antagonist, such as soluble type II IL-1 receptor and/or IL-1RAcP.Type: ApplicationFiled: August 7, 2002Publication date: March 13, 2003Inventors: John E. Sims, Dirk E. Smith
-
Publication number: 20030040543Abstract: The invention features a method of modulating SMN exon 7 expression in a subject by administering hydroxyurea to the subject.Type: ApplicationFiled: August 24, 2001Publication date: February 27, 2003Inventors: Jan-Gowth Chang, Yuh-Jyh Jong, Fuu-Jen Tsai
-
Publication number: 20030036534Abstract: The present invention relates to pharmaceutical compositions and methods for treating a retinal disorder or glaucoma using NAALADase inhibitors.Type: ApplicationFiled: May 30, 2001Publication date: February 20, 2003Inventors: Barbara S. Slusher, Krystyna Wozniak
-
Publication number: 20030027840Abstract: The present invention relates to compounds and derivatives thereof, their synthesis, and their use as estrogen receptor modulators. The compounds of the instant invention are ligands for estrogen receptors and as such may be useful for treatment or prevention of a variety of conditions related to estrogen functioning including: bone loss, bone fractures, osteoporosis, cartilage degeneration, endometriosis, uterine fibroid disease, hot flashes, increased levels of LDL cholesterol, cardiovascular disease, impairment of cognitive functioning, cerebral degenerative disorders, restinosis, gynacomastia, vascular smooth muscle cell proliferation, obesity, incontinence, and cancer, in particular of the breast, uterus and prostate.Type: ApplicationFiled: February 14, 2001Publication date: February 6, 2003Inventors: Dann LeRoy Parker, Ronald W. Ratcliffe, Robert R. Wilkening, Kenneth J. Wildonger
-
Patent number: 6511990Abstract: The present invention provides the compound having the formula: wherein each of R1 and R2 is, substituted or unsubstituted, aryl, cycloalkyl, cycloalkylamino, naphtha, pyridineamino, piperidino, t-butyl, aryloxy, arylalkyloxy, or pyridine group; wherein A is an amido moiety, —O—, —S—, —NH—, or —CH2—; and wherein n is an integer from 3 to 8. The present invention also provides a method of selectively inducing growth arrest, terminal differentiation and/or apoptosis of neoplastic cells and thereby inhibiting proliferation of such cells. Moreover, the present invention provides a method of treating a patient having a tumor characterized by proliferation of neoplastic cells. Lastly, the present invention provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically acceptable amount of the compound above.Type: GrantFiled: August 24, 2000Date of Patent: January 28, 2003Assignees: Sloan-Kettering Institute for Cancer Research, The Trustees of Columbia University in the City of New YorkInventors: Ronald Breslow, Sandro Belvedere, Leland Gershell, Thomas A. Miller, Paul A. Marks, Victoria M. Richon, Richard A. Rifkind
-
Patent number: 6509380Abstract: The present invention relates to methods of controlling iron overload in a patient in need thereof. The present invention particularly relates to methods of treating hemochromatosis and other causes of iron overload.Type: GrantFiled: December 14, 2001Date of Patent: January 21, 2003Assignee: Marshall University Research CorporationInventor: Ernest M. Walker, Jr.
-
Publication number: 20030013757Abstract: Compounds of formula I 1Type: ApplicationFiled: June 11, 2002Publication date: January 16, 2003Inventors: Ulrike Leser-Reiff, Tim Sattelkau, Gerd Zimmermann
-
Patent number: 6506764Abstract: Compounds of the formula B—X—(CH2)m—CR1R2—(CH2)n—CO—Y (I) have therapeutic utility as inhibitors of metalloproteinases etc.Type: GrantFiled: September 6, 2000Date of Patent: January 14, 2003Assignee: Darwin Discovery, Ltd.Inventors: Andrew Douglas Baxter, David Alan Owen, Duncan Hannah, John Gary Montana
-
Patent number: 6506936Abstract: The present invention relates to a novel class of organic molecules capable of inhibiting C-proteinase, and to their use to regulate, modulate and/or inhibit abnormal collagen formation as a therapeutic approach towards the treatment of fibrotic disorders.Type: GrantFiled: February 25, 1999Date of Patent: January 14, 2003Assignee: FibroGen, Inc.Inventor: Wen-Bin Ho
-
Patent number: 6503947Abstract: The invention features methods of treating cytotoxic damage in a subject comprising administering to the subject a substance which is a complement inhibitor, free radical scavenger, or both, to thereby treat cytotoxic damage. The methods of the invention can be used to treat cytotoxic damage associated with a non-thrombotic or thrombotic condition. Methods of treating thrombotic conditions such as stroke and/or ischemia in a subject, comprise administering a thrombolytic agent and a substance which is a complement inhibitor, free radical scavenger or both.Type: GrantFiled: January 27, 1999Date of Patent: January 7, 2003Assignee: Brigham and Women's HospitalInventors: Stuart A. Lipton, Dean Le, Marcus Kaul, Jonathan S. Stamler
-
Publication number: 20030004141Abstract: Medical devices, compositions and methods for treating or preventing atherosclerotic plaque rupture are disclosed. Specifically, medical devices that deliver to a treatment site metalloproteinase inhibitors (MMPI) are disclosed. The medical devices include catheters, guide wires, vascular stents, micro-particles, electronic leads, probes, sensors, drug depots, transdermal patches, and vascular patches. Representative MMPIs included zinc chelators, urea derivatives, caprolactone-based inhibitors, phoshoinamides, piperazines, sulfonamides, tertiary amines, carbamate derivatives, mercaptoalcohols, mecaptoketones, antimicrobial tertracyclines, non-antimicrobial tetracyclines, and derivatives and combinations thereof. In one embodiment a self-expanding vascular stent is coated with at least one MMPI and deployed at a site within an artery where vulnerable plaque has been identified.Type: ApplicationFiled: March 8, 2002Publication date: January 2, 2003Inventor: David L. Brown
-
Patent number: 6500983Abstract: Novel hydroxamic acid compounds, e.g., of formula I, wherein R1, R2, R3 and R4 are as defined, are found to be useful as pharmaceuticals, e.g., for the suppression of TNF release and the treatment of autoimmune and inflammatory diseases, e.g., multiple sclerosis and rheumatoid arthritis. Methods of making the compounds, novel intermediates, and pharmaceutical compositions comprising the compounds are provided.Type: GrantFiled: October 9, 2001Date of Patent: December 31, 2002Assignee: Novartis AGInventors: Georg Kottirsch, Ulf Neumann
-
Publication number: 20020198241Abstract: A method for the treatment of bacterial infections in humans and non-human mammals, which comprises inhibiting bacterial growth by administering to a subject an antibacterially effective dose of a compound of formula (I) or a pharmaceutically or veterinarily acceptable salt thereof: 1Type: ApplicationFiled: June 26, 2002Publication date: December 26, 2002Applicant: British Biotech Pharmaceuticals Ltd.Inventors: Michael George Hunter, Paul Raymond Beckett, John Martin Clements, Mark Whittaker, Zoe Marie Spavold
-
Publication number: 20020198176Abstract: The present invention relates to methods of treating psoriasis by inhibiting one or more matrix metalloproteinase enzymes (“MMPs”). It is based, at least in part, on the discovery that the expression patterns of certain MMPs and related molecules are altered in patients suffering from psoriasis, relative to normal subjects. Certain expression patterns are altered even in unaffected skin of psoriasis-afflicted patients, although aberrancies are more pronounced in psoriatic lesions. In various non-limiting embodiments, the present invention provides for methods of treating psoriasis, including preventing the development of new psoriatic lesions, comprising administering, to subjects in need of such treatment, effective concentrations of compounds which inhibit the enzymatic activity of one or more MMP. Suitable inhibitors include tetracycline and its derivatives and various hydroxymate, carboxylic acid, and phosphonic acid derivatives.Type: ApplicationFiled: July 29, 2002Publication date: December 26, 2002Inventor: Raul Fleischmajer
-
Patent number: 6495597Abstract: Compounds of formula (I) wherein R4 is an ester or thioester group and R, R1, R2 and R3 are as defined in the specification, inhibit proliferation of tumor cells.Type: GrantFiled: October 5, 2000Date of Patent: December 17, 2002Assignee: British Biotech Pharmaceuticals Ltd.Inventors: Andrew Paul Ayscough, Lisa Marie Pratt, Alan Hastings Drummond
-
Patent number: 6492422Abstract: Tricyclic sulfonamide compounds and derivatives are described as well as methods for the preparation and pharmaceutical compositions of same, which are useful as inhibitors of matrix metalloproteinases, particularly gelatinase A, collagenase-3, and stromelysin-1 and for the treatment of multiple sclerosis, atherosclerotic plaque rupture, aortic aneurysm, heart failure, left ventricular dilation, restenosis, periodontal disease, or other autoimmune or inflammatory disorders dependent upon tissue invasion by leukocytes or other activated migrating cells, acute and chronic neurodegenerative disorders including stroke, head trauma, spinal cord injury, Alzheimer's disease, amyotrophic lateral sclerosis, cerebral amyloid angiopathy, AIDS, Parkinson's disease, Huntington's disease, prion diseases, myasthenia gravis, and Duchenne's muscular dystrophy.Type: GrantFiled: March 27, 2002Date of Patent: December 10, 2002Assignee: Warner-Lambert CompanyInventors: Patrick Michael O'Brien, Joseph Armand Picard, Drago Robert Sliskovic
-
Publication number: 20020183388Abstract: The present invention provides a method of inhibiting growth of solid tumors in an animal which comprises administering an effective amount of trichostatin A (TSA) to an animal in need of such treatment. The present invention also provides a method of inhibiting growth of solid tumors in an animal which comprises administering an effective amount of a histone deacetylase inhibitor and a retinoid to an animal in need of such treatment. Examples of solid tumors which may be treated using the methods of the invention include but are not limited to carcinomas of the head and neck, breast, skin, kidney, oral cavity, colon, prostate, pancreas and lung.Type: ApplicationFiled: February 1, 2002Publication date: December 5, 2002Inventors: Lorraine J. Gudas, David Nanus
-
Publication number: 20020177548Abstract: Combination therapies are provided for the treatment of proliferative disorders which use a pentafluorobenzenesulfonamide of formula I and an antineoplastic agent such as gemcitabine or paclitaxel.Type: ApplicationFiled: November 2, 2001Publication date: November 28, 2002Applicant: Tularik Inc.Inventors: Susan Schwendner, Pieter Timmermans, Jacqueline Walling
-
Publication number: 20020173508Abstract: An aromatic sulfonyl alpha-hydroxy hydroxamic acid compound that inter alia inhibits matrix metalloprotease activity is disclosed, as is a treatment process that comprises administering a contemplated aromatic sulfonyl alpha-hydroxy hydroxamic acid compound in an MMP enzyme-inhibiting effective amount to a host having a condition associated with pathological matrix metalloprotease activity.Type: ApplicationFiled: December 3, 2001Publication date: November 21, 2002Inventors: John N. Freskos, Terri L. Boehm, Brent V. Mischke, Robert M. Heintz, Joseph J. McDonald, Gary A. DeCrescenzo, Susan C. Howard
-
Publication number: 20020165167Abstract: Compounds of formula (I) are antibacterials: 1Type: ApplicationFiled: April 30, 2002Publication date: November 7, 2002Applicant: British Biotech Pharmaceuticals Ltd.Inventors: Michael George Hunter, Raymond Paul Beckett, John Martin Clements, Mark Whittaker, Stephen John Davies, Lisa Marie Pratt, Zoe Marie Spavold, Steven Launchbury
-
Patent number: 6476027Abstract: An N-hydroxy sulfonyl butanamide compound that inter alia inhibits matrix metalloprotease activity is disclosed as are a treatment process that comprises administering a contemplated N-hydroxy sulfonyl butanamide compound in a MMP enzyme-inhibiting effective amount to a host having a condition associated with pathological matrix metalloprotease activity.Type: GrantFiled: December 6, 1999Date of Patent: November 5, 2002Assignee: Monsanto CompanyInventors: Clara I. Villamil, John N. Freskos, Brent V. Mischke, Patrick B. Mullins, Robert M. Heintz, Daniel P. Getman, Joseph J. McDonald, Gary A. DeCrescenzo, Thomas E. Barta, Daniel P. Becker
-
Publication number: 20020161049Abstract: The present invention relates to the use of creatine compounds including creatine, creatine phosphate or analogs of creatine, such as cyclocreatine, for treating diseases of the nervous system. Creatine compounds can be used as therapeutically effective agents against a variety of diseases of the nervous system such as diabetic and toxic neuropathies, peripheral nervous system diseases, Alzheimer disease, Parkinson's disease, stroke, Huntington's disease, amyotropic lateral sclerosis, motor neuron disease, traumatic nerve injury, multiple sclerosis, dysmyelination and demyelination disorders, and mitochondrial diseases.Type: ApplicationFiled: May 7, 1997Publication date: October 31, 2002Inventors: RIMA KADDURAH-DAOUK, GHALEB DAOUK, M. FLINT BEAL
-
Publication number: 20020155179Abstract: Inhibitors of integrin-linked kinase (ILK) are used in the treatment of inflammatory disease, including cutaneous inflammatory diseases, such as psoriasis, scleroderma, systemic lupus erythematosus and atopic dermatitis.Type: ApplicationFiled: November 30, 2001Publication date: October 24, 2002Inventors: Shoukat Dedhar, Greg Hannigan, David W.C. Hunt, Jing-Song Tao, Ladan Fazli
-
Patent number: 6465468Abstract: The subject invention concerns methods and compounds that have utility in the treatment of a condition associated with matrix metalloproteinase, ADAM or ADAM-TS enzymes, a condition that is mediated by TNF &agr; or a condition involving a membrane-shedding event that is mediated by a metalloproteinase. Compounds of the invention are of formula I (B)2N—X—(CH2)m—W—(CR1R2)n—COY (I) wherein n=0 or 1; m=0 or 1; X is S(O)1-2; Y is OH or NHOH; W is aryl or heteroaryl; and the other groups are as defined herein.Type: GrantFiled: March 22, 2000Date of Patent: October 15, 2002Assignee: Darwin Discovery LimitedInventors: Andrew Douglas Baxter, David Alan Owen, Duncan Batty, Robert John Watson
-
Publication number: 20020143052Abstract: Histone deacetylase is a metallo-enzyme with zinc at the active site. Compounds having a zinc-binding moiety, such as, for example, a hydroxamic acid group or a carboxylic acid group, can inhibit histone deacetylase. Histone deacetylase inhibition can repress gene expression, including expression of genes related to tumor suppression. Accordingly, inhibition of histone deacetylase can provide an alternate route for treating cancer, hematological disorders, e.g., hemoglobinopathies, and genetic related metabolic disorders, e.g., cystic fibrosis and adrenoleukodystrophy.Type: ApplicationFiled: March 27, 2001Publication date: October 3, 2002Inventors: Hsuan-Yin Lan-Hargest, Robert J. Kaufman, Norbert L. Wiech
-
Publication number: 20020137776Abstract: This invention relates to therapeutic and prophylactic agents for neoplasms which comprise a fused heterocyclic compound or a pharmaceutically acceptable salt thereof as an active ingredient; to the use of such a compound in the preparation of a medicament for the treatment and prevention of neoplasms; and to a method for treatment and prevention of neoplasms which comprises administering a pharmaceutically effective amount of such a compound to a warm-blooded animal (preferably a human).Type: ApplicationFiled: January 18, 2002Publication date: September 26, 2002Applicant: SANKYO COMPANY, LIMITEDInventors: Shinichi Kurakata, Kosaku Fujiwara, Takashi Fujita
-
Publication number: 20020132778Abstract: The invention provides methods and compositions relating to Kuz involvement in angiogenesis.Type: ApplicationFiled: February 6, 2002Publication date: September 19, 2002Applicant: The Regents of the University of CaliforniaInventors: Duojia Pan, Gerald M. Rubin, Hongbing Zhang
-
Patent number: 6444704Abstract: Matrix metalloproteinases (MMPs) are a group of enzymes that have been implicated in the pathological destruction of connective tissue and basement membranes. These zinc containing endopeptidases consist of several subsets of enzymes including collagenases, stromelysins and gelatinases. TNF-&agr; converting enzyme (TACE), a pro-inflammatory cytokine, catalyzes the formation of TNF-&agr; from membrane bound TNF-&agr; precursor protein. It is expected that small molecule inhibitors of MMPs and TACE therefore have the potential for treating a variety of disease states. The present invention provides low molecular weight, non-peptide inhibitors of matrix metalloproteinases (MMPs) and TNF-&agr; converting enzyme (TACE) for the treatment of arthritis, tumor metastasis, tissue ulceration, abnormal wound healing, periodontal disease, bone disease, diabetes (insulin resistance) and HIV infection.Type: GrantFiled: August 17, 2000Date of Patent: September 3, 2002Assignee: American Home Products CorporationInventors: Aranapakam Mudumbai Venkatesan, Janniee Lea Baker
-
Patent number: 6441042Abstract: Compounds of formula (I) are antibacterials wherein: R1 represents hydrogen, or C1-C6 alkyl or C1-C6 alkyl substituted by one or more halogen atoms; R2 represents a group R10—(X)n—(ALK)m— wherein R10 represents hydrogen, or a C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, aryl, or heterocyclyl group, any of which may be unsubstituted or substituted by (C1-C6)alkyl, (C1-C6)alkoxy, hydroxy, mercapto, (C1-C6)alkylthio, amino, halo (including fluoro, chloro, bromo and iodo), trifluoromethyl, cyano, nitro, —COOH, —CONH2, —COORA, —NHCORA, —CONHRA, —NHRA, —NRARB, or —CONRARB wherein RA and RB are independently a (C1-C6)alkyl group, and ALK represents a straight or branched divalent C1-C6 alkylene, C2-C6 alkenylene, or C2-C6 alkynylene radical, and may be interrupted by one or more non-adjacent —NH—, —O— or —S— linkages, X represents —NH—, —O— or —S—, and m and n are indepeType: GrantFiled: November 15, 2000Date of Patent: August 27, 2002Assignee: British Biotech Pharmaceuticals LimitedInventors: Michael George Hunter, Raymond Paul Beckett, John Martin Clements, Mark Whittaker, Zoe Marie Spavold
-
Publication number: 20020111362Abstract: A method for treating diseases associated with abnormal cell proliferation comprises delivering to a patient in need of treatment a compound selected from the group consisting of 20(S)-camptothecin, analog of 20(S)-camptothecin, derivative of 20(S)-camptothecin, prodrug of 20(S)-camptothecin, and pharmaceutically active metabolite of 20(S)-camptothecin, in combination with an effective amount of one or more agents selected from the group consisting of alkylating agent, antibiotic agent, an alkylating agent, antibiotic agent, antimetabolic agent, hormonal agent, plant-derived agent, anti-angiogenesis agent and biologic agent. The method can be used to treat benign tumors, malignant or metastatic tumors, leukemia and diseases associated with abnormal angiogenesis.Type: ApplicationFiled: April 22, 2002Publication date: August 15, 2002Inventor: Joseph Rubinfeld
-
Publication number: 20020103239Abstract: A sulfonyl divalent aromatic or heteroaromatic ring hydroxamic acid compound that inter alia inhibits matrix metalloprotease activity is disclosed as are a treatment process that comprises administering a contemplated sulfonyl divalent aromatic or heteroaromatic ring hydroxamic acid compound in a MMP enzyme-inhibiting effective amount to a host having a condition associated with pathological matrix metalloprotease activity.Type: ApplicationFiled: November 29, 2001Publication date: August 1, 2002Inventors: Louis J. Bedell, Joseph J. McDonald, Thomas E. Barta, Daniel P. Becker, Shashidhar N. Rao, John N. Freskos, Brent V. Mischke, Daniel P. Getman, Gary A. DeCrescenzo
-
Publication number: 20020098185Abstract: The invention pertains to methods for treating medical disorders characterized by elevated levels or abnormal expression of IL-18 by administering an IL-18 antagonist, such as soluble IL-18 receptor, a soluble IL-18 binding protein and/or an antibody.Type: ApplicationFiled: January 18, 2002Publication date: July 25, 2002Inventors: John E. Sims, Kendall M. Mohler, Teresa L. Born
-
Publication number: 20020099035Abstract: Compounds of the formula: 1Type: ApplicationFiled: January 24, 2001Publication date: July 25, 2002Inventors: Vincent P. Sandanayaka, Arie Zask, Aranapakam M. Venkatesan, Jannie L. Baker, Lalitha Krishnan, Sreenivasulu Megati, Joseph Zeldis
-
Publication number: 20020086890Abstract: Compounds of the formula: 1Type: ApplicationFiled: December 21, 2001Publication date: July 4, 2002Applicant: American Cyanamid CompanyInventors: Jeremy I. Levin, Aranapakam M. Venkatesan, James M. Chen, Arie Zask, Vincent P. Sandanayaka, Mila T. Du, Jannie L. Baker
-
Publication number: 20020082200Abstract: Inhibitors of matrix metalloproteases such as collagenase are capable of inhibiting the release of human soluble CD23 and are therefore useful in the treatment and prophylaxis of conditions in which an excess of s-CD23 is implicated, such as allergy and autoimmune disease.Type: ApplicationFiled: January 3, 2002Publication date: June 27, 2002Applicant: SmithKline Beecham p.1.c.Inventors: Gary Christie, Beverly Jane Weston
-
Publication number: 20020077291Abstract: The present invention provides pharmaceutical compositions and methods for treating cell proliferative disorders, such as tumors, in a subject, utilizing TGF-&agr; or functional fragments thereof. Optionally, a chemotherapeutic agent is administered in combination with TGF-&agr; or fragments thereof.Type: ApplicationFiled: September 20, 2001Publication date: June 20, 2002Inventors: Alan Upshall, Daniel R. Twardzik, Andrzej Sledziewski
-
Publication number: 20020076736Abstract: The present invention relates to a method for diagnosing, treating, and preventing conditions associated with altered expression or activity of laminin 5 using BMP-1 inhibitors.Type: ApplicationFiled: May 11, 2001Publication date: June 20, 2002Inventors: Paul R. Findell, M. Peter Marinkovich
-
Publication number: 20020071832Abstract: This invention provides methods of treating cancer employing mutant herpes viruses and anticancer agents, such as chemotherapeutic drugs.Type: ApplicationFiled: June 1, 2001Publication date: June 13, 2002Inventors: Yuman Fong, Joseph Bennett, Henrik Petrowsky
-
Patent number: 6403647Abstract: The invention relates to novel compositions and to methods for the pulsed administration of compositions to a patient or to cells in vitro for the treatment of human blood disorders. Compositions contain chemical compounds that stimulate the expression of fetal hemoglobin and/or stimulate the proliferation of red blood cells, white blood cells and platelets in patients and ex vivo for reconstitution of hematopoiesis in vivo. These methods are useful to treat or prevent the symptoms associated with anemia, sickle cell disease, thalassemia and other blood disorders. The, invention also relates to methods for the pulsed administration of compositions to patients for the treatment and prevention of cell proliferative disorders including deficiencies such as cytopenia and malignancies such as viral-induced tumors, other forms of neoplasia and for expansion of cells for hematopoietic transplantation. Pulsed administration has been shown to be more effective than continuous therapy in patients tested.Type: GrantFiled: April 25, 2000Date of Patent: June 11, 2002Inventor: Susan P. Perrine
-
Publication number: 20020065282Abstract: The present invention provides compounds of formula I 1Type: ApplicationFiled: December 4, 2001Publication date: May 30, 2002Inventors: Guy Georges, Adelbert Grossmann, Tim Sattelkau, Wolfgang Schaefer, Ulrich Tibes
-
Publication number: 20020055543Abstract: Compounds' of formula (I) and pharmaceutically acceptable salts thereof, wherein R1, R2, AA and Y are as defined herein, inhibit phosphodiesterase type IV or inhibit the production of tumor necrosis factor, and therefore are useful in the treatment of certain conditions and diseases including asthma, arthritis, and sepsis.Type: ApplicationFiled: January 25, 2001Publication date: May 9, 2002Inventor: Edward F. Kleinman
-
Patent number: 6384236Abstract: Compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1, R2, AA and Y are as defined herein, inhibit phosphodiesterase type IV or inhibit the production of tumor necrosis factor, and therefore are useful in the treatment of certain conditions and diseases including asthma, arthritis, and sepsis.Type: GrantFiled: January 25, 2001Date of Patent: May 7, 2002Assignee: Pfizer IncInventor: Edward F. Kleinman
-
Patent number: 6380258Abstract: A sulfonyl divalent aromatic or heteroaromatic ring hydroxamic acid compound that inter alia inhibits matrix metalloprotease activity is disclosed as are a treatment process that comprises administering a contemplated sulfonyl divalent aromatic or heteroaromatic ring hydroxamic acid compound in a MMP enzyme-inhibiting effective amount to a host having a condition associated with pathological matrix metalloprotease activity.Type: GrantFiled: June 24, 1999Date of Patent: April 30, 2002Assignee: G. D. Searle, L.L.C.Inventors: Louis J. Bedell, Joseph J. McDonald, Thomas E. Barta, Daniel P. Becker, Shashidhar N. Rao, John N. Freskos, Brent V. Mischke, Daniel P. Getman, Gary A. DeCrescenzo